| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/CIRCRESAHA.112.276444 |
| P698 | PubMed publication ID | 22927331 |
| P50 | author | Konstantinos Stellos | Q39374538 |
| P2093 | author name string | Florian Lang | |
| Evi Schmid | |||
| Patrick Münzer | |||
| Tanja Schönberger | |||
| Andreas E May | |||
| Meinrad Gawaz | |||
| Peter Seizer | |||
| Sergios Gatidis | |||
| Eva-Maria Schmidt | |||
| Oliver Borst | |||
| Syeda T Towhid | |||
| P2860 | cites work | CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway | Q33909085 |
| P433 | issue | 10 | |
| P921 | main subject | inflammation | Q101991 |
| P304 | page(s) | 1297-1307 | |
| P577 | publication date | 2012-08-27 | |
| P1433 | published in | Circulation Research | Q2599020 |
| P1476 | title | The inflammatory chemokine CXC motif ligand 16 triggers platelet activation and adhesion via CXC motif receptor 6-dependent phosphatidylinositide 3-kinase/Akt signaling. | |
| P478 | volume | 111 |
| Q33676193 | Activated platelets interfere with recruitment of mesenchymal stem cells to apoptotic cardiac cells via high mobility group box 1/Toll-like receptor 4-mediated down-regulation of hepatocyte growth factor receptor MET |
| Q42385774 | CXCL16: a chemokine-causing chronic kidney disease |
| Q34501912 | CXCR6 deficiency attenuates pressure overload-induced monocytes migration and cardiac fibrosis through downregulating TNF-α-dependent MMP9 pathway. |
| Q47720267 | Cigarette Smoke Increases Endothelial CXCL16-Leukocyte CXCR6 Adhesion In Vitro and In Vivo. Potential Consequences in Chronic Obstructive Pulmonary Disease. |
| Q35123323 | Correlations of SELE and SELP genetic polymorphisms with myocardial infarction risk: a meta-analysis and meta-regression |
| Q92563879 | Disruption of CXCR6 Ameliorates Kidney Inflammation and Fibrosis in Deoxycorticosterone Acetate/Salt Hypertension |
| Q54524513 | Dynamic adhesion of eryptotic erythrocytes to immobilized platelets via platelet phosphatidylserine receptors. |
| Q34104052 | Enhanced Orai1 and STIM1 expression as well as store operated Ca2+ entry in therapy resistant ovary carcinoma cells |
| Q50249518 | Extracellular Cyclophilin A Augments Platelet-Dependent Thrombosis and Thromboinflammation |
| Q58802739 | Identification of key lipids critical for platelet activation by comprehensive analysis of the platelet lipidome |
| Q53516281 | Impact of the serum- and glucocorticoid-inducible kinase 1 on platelet dense granule biogenesis and secretion. |
| Q94452080 | LipidCreator workbench to probe the lipidomic landscape |
| Q53647042 | Loss of oligophrenin1 leads to uncontrolled Rho activation and increased thrombus formation in mice. |
| Q38095124 | Platelet biology: the role of shear |
| Q34019069 | Platelets and their chemokines in atherosclerosis-clinical applications |
| Q38300645 | Platelets are an unindicted culprit in the development of endometriosis: clinical and experimental evidence |
| Q92097995 | Relation between mean platelet volume and C-reactive protein |
| Q42170536 | SDF-1α is a novel autocrine activator of platelets operating through its receptor CXCR4. |
| Q34519103 | Sphingosine kinase 1 (Sphk1) negatively regulates platelet activation and thrombus formation |
| Q38284002 | Systems biology of platelet-vessel wall interactions |
| Q38333255 | The CXC chemokine receptors of fish: Insights into CXCR evolution in the vertebrates. |
| Q36476906 | The perioperative time course and clinical significance of the chemokine CXCL16 in patients undergoing cardiac surgery |
| Q38221746 | The serum- & glucocorticoid-inducible kinase in the regulation of platelet function |
| Q51590709 | The structural investigation of glycosaminoglycan binding to CXCL12 displays distinct interaction sites. |
| Q38144933 | Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer |
| Q38378483 | Viscoelasticity and Ultrastructure in Coagulation and Inflammation: Two Diverse Techniques, One Conclusion |
| Q49166713 | microRNA-612 is downregulated by platelet-derived growth factor-BB treatment and has inhibitory effects on vascular smooth muscle cell proliferation and migration via directly targeting AKT2. |
Search more.